Efficacy and Safety of Biosimilar QL1101 Compared with Avastin in Patients with Non-Squamous Non-Small Cell Lung Cancer

被引：1

作者：

Han, B. ^{[1
]}

Li, K. ^{[2
]}

Chu, T. ^{[1
]}

Bi, M. ^{[3
]}

Zhang, H. ^{[4
]}

Yu, Y. ^{[5
]}

Shi, J. ^{[6
]}

Zhang, X. ^{[7
]}

Chen, Z. ^{[8
]}

Han, C. ^{[9
]}

Bai, T. ^{[9
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm Med, Shanghai, Peoples R China

[2] Tianjin Canc Hosp, Tianjin, Peoples R China

[3] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Anhui, Peoples R China

[4] Fourth Mil Med Univ Peoples Liberat Army, Tangdu Hosp, Xian, Shaanxi, Peoples R China

[5] Harbin Med Univ, Canc Hosp, Harbin, Heilongjiang, Peoples R China

[6] Linyi Canc Hosp, Linyi, Shandong, Peoples R China

[7] Qingdao Univ, Affiliated Hosp, Qingdao, Shandong, Peoples R China

[8] Anhui Med Univ, Hosp 2, Hefei, Anhui, Peoples R China

[9] Qilu Pharmaceut Co Ltd, Jinan, Shandong, Peoples R China

来源：

关键词：

QL1101; Bevacizumab; biosimilarity;

D O I：

10.1016/j.jtho.2019.08.718

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P1.01-03

引用

页码：S355 / S355

页数：1